Shenzhen Foncoo Pharmaceutical Co., Ltd., a technically creative medicine producer, was approved to list on New Three Board May 4^st, 2016, which allows Chinese middle and small size corporations to transfer shares. The stock ID is 837090. Our headquarters is located in Hi-tech Zoon, Nanshan District, Shenzhen, while production base in Lushun Economic Development Zoon, Dalian.

The mission of Foncoo Company is to improve the physical and mental health of human beings. Adhering to the core values of Customer First, Employee Achievement, Creation and Innovation, Openness and Transparency, Trust and Respect, the Company has built a comprehensive competitive management system to ensure implementation of its mission and strive to become the most respected enterprise in the field of mental health

After almost 20-year pharmaceutical marketing, Foncoo has perfected its marketing model as a system featuring “professional products + professional marketing”, and a strong marketing network has been established for the country’s prescription medicine market, especially in the field of psychiatry. Currently our sales cover over 5,000 hospitals in 31 provinces, cities and autonomous areas. Based on advanced digital management system, the company supervises operation every moment to ensure the efficiency in business management.
   
Thanks to efficient marketing model, Foncoo has built up long-term cooperative ties with Dr. Reddy's Laboratories, Harbin Pharmaceutical Group Co., Ltd., Guangxi Wuzhou pharmaceutical (Group) Co., Ltd., and Guangxi Yulin Pharmaceutical Group Co., Ltd. Now across the country the company is selling 6 products, The treatment field of products of the Company covers psychiatry, neurology, cardiology and cerebrovascular, orthopedics and other departments.

Product development indicates the core competitiveness of a pharmaceutical corporation and is also the basic power for a corporation’s sustainable development. Foncoo, which is adhering to its core values, through making a platform for R&D and cooperation, linking program management and outsourcing R&D, integrating technical resources and products, and focusing on genetic drug production and development of new medicine, has established a competitive model for product development.